Profile: Mylan Technologies, Inc. is associated with the design, development and manufacture of transdermal drug delivery systems. We also produce components for the medical device and transdermal industries. Our transdermal product list comprises of nitroglycerin, estradiol and fentanyl transdermal systems. Our Fentanyl transdermal patch provides continuous delivery of fentanyl over 72 hours for the management of persistent, moderate to severe chronic pain in patients already receiving opioid treatment, who require continuous & extended opioid administration and cannot be managed by other means. We offer standard and custom component materials needed for transdermal drug delivery systems. Our standard component materials comprise of Medifilm®, Mediflex®, Medirelease® and Mediderm® . Our Medifilm® line of extruded and co-extruded films feature four standard film categories, each with distinct characteristics to meet the specific requirements of wound care, ostomy and transdermal applications.

The company was founded in 1961, has revenues of USD 50-100 Million, has ~250 employees and is ISO 9001 certified. NYSE:MYL (SEC Filings)